FDA, EMA Valsartan Update, New Data on Cancer Risk FDA, EMA Valsartan Update, New Data on Cancer Risk

The FDA and EMA report a possible second carcinogen in previously withdrawn vasartan products, while a new analysis finds no increased cancer risk in those who previously took contaminated valsartan.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news